Recently, Biokin Pharmaceutical organized a conference for the entire company to study the important speeches at the Central Economic Work Conference and its spirit.

The Central Economic Work Conference comprehensively summarized the economic work in 2024, analyzed the current economic situation, elaborated the major theoretical and practical issues, and made comprehensive arrangements for 2025, which has provided political and ideological guidance, shown the direction and provided the fundamental guideline for the current and future economic work.

It was noted at the meeting that it is necessary to lead the development of new quality productive forces with scientific and technological innovation, and to build a modernized industrial system; the meeting stressed the need to strengthen basic research, achieve breakthroughs in core technologies in key fields, lay out major scientific and technological projects ahead of time, and to carry out large-scale application and demonstration of new technologies, products and scenarios.

The company stated the need to study and implement the spirit of the Central Economic Work Conference, realize high-quality development of the listed company and enhance investor returns. As a biopharmaceutical company, Biokin Pharmaceutical focuses on the frontier of global biopharmaceuticals. Driven by the unmet clinical needs, we have a full range of drug research and development capabilities, including ADC drugs, large molecule biopharmaceuticals and small molecule chemical drugs, and possesses a complete lifecycle commercialization operation capability covering “R&D, production and marketing”, ranging from intermediates, APIs to preparations. It is also a biopharmaceutical company with integrated advantages from intermediates to APIs to formulations, covering “R&D - production - marketing” complete life cycle commercialization operation capability.

In the next step, the company will continue to improve the quality of the company's development based on global competitiveness, integrate into the global innovation system, and build up a sustained innovation capability. The company will focus on the field of tumor treatment for breakthrough efficacy and breakthrough innovation for the benefit of patients.